GlassScriptPhysician profile
Emily A Moore
NPI 1730436668
$8,801.31
in general payments reported to CMS, 2019-2025
30 companies · $2,259 in 2025
The $2,259 reported for 2025 was more than what 94% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,450 · 2022: $1,276 · 2023: $1,834 · 2024: $1,983 · 2025: $2,259.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,021 · Education: $54.73.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,021.34 |
| Education | $54.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,483.71 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $957.81 | 2021-2025 | Spravato, Invega Sustenna, Invega Trinza |
| Corium, LLC | $954.75 | 2021-2025 | Azstarys |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $838.74 | 2021-2025 | Caplyta |
| Alkermes, INC. | $820.43 | 2021-2025 | Aristada, Lybalvi, Aristada Initio |
| Supernus Pharmaceuticals, INC. | $353.69 | 2023-2025 | Qelbree, Qelbree |
| Neurocrine Biosciences, INC. | $350.30 | 2022-2025 | Ingrezza |
| Axsome Therapeutics, INC. | $321.32 | 2023-2025 | Auvelity |
| Vanda Pharmaceuticals INC. | $308.47 | 2021-2025 | Fanapt |
| Takeda Pharmaceuticals U.S.A., INC. | $257.62 | 2021-2023 | Trintellix |
| Otsuka America Pharmaceutical, INC. | $246.91 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Teva Pharmaceuticals USA, INC. | $245.82 | 2021-2025 | Austedo Xr, Uzedy, Austedo Xr |
| Bausch Health US, LLC | $224.23 | 2021-2025 | Aplenzin, Wellbutrin |
| Ironshore Pharmaceuticals INC. | $215.17 | 2022-2024 | Jornay Pm |
| E.R. Squibb & Sons, L.L.C. | $202.68 | 2025 | Cobenfy |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $202.52 | 2021-2022 | |
| Lundbeck LLC | $183.56 | 2021-2024 | Rexulti |
| Jazz Pharmaceuticals INC. | $171.17 | 2021-2022 | |
| Sunovion Pharmaceuticals INC. | $143.41 | 2021-2022 | |
| Avanir Pharmaceuticals, INC. | $67.34 | 2021-2022 | |
| Avion Pharmaceuticals | $45.44 | 2023 | Methylphenidate Hydrochloride |
| Collegium Pharmaceutical, INC. | $37.40 | 2025 | Jornay Pm |
| Sage Therapeutics, LLC | $34.06 | 2021-2024 | |
| Adlon Therapeutics L.P. | $29.46 | 2021 | |
| Almatica Pharma LLC | $27.52 | 2021-2022 | |
| Idorsia Pharmaceuticals US INC | $19.16 | 2025 | Quviviq |
| Harmony Biosciences LLC | $16.11 | 2025 | |
| Noven Therapeutics, LLC | $15.00 | 2023 | Secuado |
| Merck Sharp & Dohme LLC | $14.19 | 2022 | |
| Currax Pharmaceuticals LLC | $13.32 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emily Moore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.